Efficacy of ebastine in the control of nasal congestion associated with allergic rhinitis

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 25, Issue 2, 2003, Pages 111-115

  Ratnert, Paul H ^a   Hampel Jr , F ^b   Gispert, J ^c  

^a Sylvana Research   (United States)

^b Central Texas Health Research   (United States)

^c Almirall Prodesfarma SA ^*  (Spain)

Author keywords

Allergic rhinitis; Antiinflammatory; Ebastine; Nasal congestion

Indexed keywords

EBASTINE; LORATADINE; PLACEBO;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NOSE CONGESTION; RAGWEED; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY;

ADULT; AMBROSIA; BUTYROPHENONES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H1 ANTAGONISTS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LORATADINE; MALE; NASAL OBSTRUCTION; PIPERIDINES; RHINITIS, ALLERGIC, SEASONAL;

EID: 0037353692     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2003.25.2.723684     Document Type: Article

References (25)

1. Bousquet, J. Antihistamines in severe/chronic rhinitis. Clin Exp Allergy 1998, 28 (Suppl 6): 49-53.
2. Davies, R.J. Efficacy and tolerability comparison of ebastine 10 and 20 mg with loratadine 10 mg: A double-blind, randomised study in patients with perennial allergic rhinitis. Clin Drug Invest 1998, 16: 413-20.
3. Bousquet, J., Gaudano, E.M., Palma Carlos, A.G., Staudinger, H. A 12-week, placebo-controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis. Multicentre Study Group. Allergy 1999, 54: 562-8.
4. Hurst, M., Spencer, C.M. Ebastine-An update of its use in allergic disorders. Drugs 2000, 59: 981-1006.
5. De Molina, M., Cadahia, A., Cano, L., Sanz, A. Efficacy and tolerability of ebastine at two dose levels in the treatment of seasonal allergic rhinitis. Drug Invest 1989, 1: 40-6.
6. Storms, W.W. Clinical studies of the efficacy and tolerability of ebastine 10 or 20 mg once daily in the treatment of seasonal allergic rhinitis in the US. Drugs 1996, 52: 20-5.
7. Gehanno, P., Bremard-Oury, C., Zeisser, P. Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults. Ann Allergy Asthma Immunol 1996, 76: 507-12.
8. Luria, X., Robert, M., Antepara, I. et al. A double-blind placebo controlled study of the efficacy and tolerability of ebastine and loratadine in seasonal allergic rhinitis patients (abstract). Allergy 1995, 50: 199.
9. Rather, P.H., Lira, J.C., Georges, G.C. Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. J Allerg Clin Immunol 2000, 105: 1101-7.
10. Haria, M., Fitton, A., Peters, D.H. Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs 1994, 48: 617-37.
11. Horak, F., Stubner, U.P. Comparative tolerability of second generation antihistamines. Drug Saf 1999, 20: 385-401.
12. Salmun, L.M. Antihistamines in late-phase clinical development for allergic disease. Expert Opin Investig Drugs 2002, 11: 259-73.
13. Corey, J.P., Houser, S.M., Ng, B.A. Nasal congestion: A review of its etiology, evaluation, and treatment. Ear Nose Throat J 2000, 79: 690-3.
14. Naclerio, R. Clinical manifestations of the release of histamine and other inflammatory mediators. J Allergy Clin Immunol 1999, 103: S382-5.
15. Bachert, C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy 2001, 56: 14-20.
16. Nayak, A.S., Schenkel, E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001, 56: 1077-80.
17. Ciprandi, G., Cosentino, C., Milanese, M., Mondino, C., Canonica, G.W. Fexofenadine reduces nasal congestion in perennial allergic rhinitis. Allergy 2001, 56: 1068-70.
18. Campbell, A., Michel, F.B., Bremard-Oury, C., Crampette, L., Bousquet, J. Overview of allergic mechanisms. Ebastine has more than an antihistamine effect. Drugs 1996, 52: 15-9.
19. Roberts, D.J. A preclinical overview of ebastine. Studies on the pharmacological properties of a novel histamine H1 receptor antagonist. Drugs 1996, 52: 8-14.
20. A multicenter, double-blind, placebo controlled, randomized comparative study to compare the efficacy and safety of ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo, all given once daily for four weeks in the treatment of seasonal allergic rhinitis (Study CM.030.ALGY). Almirall Prodesfarma, S.A. Data on file 2002.
21. A multicenter, double-blind, placebo controlled, randomized comparative study to compare the efficacy and safety of ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo, all given once daily for four weeks in the treatment of seasonal allergic rhinitis (Study CM.031.ALGY). Almirall Prodesfarma, S.A. Data on file 2002.
22. A multicenter, double-blind, placebo controlled, randomized comparative study to compare the efficacy and safety of ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo, all given once daily for four weeks in the treatment of seasonal allergic rhinitis (Study EBA.GMA.402). Almirall Prodesfarma, S.A. Data on file 2001.
23. May, J.R. Allergic rhinitis. Pharmacotherapy 1999: 1479-88.
24. Balbani, A.P.S., Duarte, J.G., De Mello, J.F., Jr., D'Antonio, W.E.P., Camara, J., Butugan, O. Toxicity of drugs used for treatment of rhinitis: A reminder to the otorhinolaryngologist. Am J Rhinol 2000, 14: 77-82.
25. Tripathi, A., Patterson, R. Impact of allergic rhinitis treatment on quality of life. Pharmacoeconomics 2001, 19: 891-9.